Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
Protagonist Therapeutics Inc (NASDAQ: PTGX) closed the day trading at $87.41 up 1.58% from the previous closing price of $86.05. In other words, the price has increased by $1.58 from its previous closing price. On the day, 0.66 million shares were traded. PTGX stock price reached its highest trading level at $88.13 during the session, while it also had its lowest trading level at $84.88.
Ratios:
For a better understanding of PTGX, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.48 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 85.77. For the most recent quarter (mrq), Quick Ratio is recorded 13.05 and its Current Ratio is at 13.05. In the meantime, Its Debt-to-Equity ratio is 0.02 whereas as Long-Term Debt/Eq ratio is at 0.01.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on September 17, 2025, initiated with a Overweight rating and assigned the stock a target price of $72.
On September 12, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $73.
On June 17, 2025, Citigroup started tracking the stock assigning a Buy rating and target price of $72.Citigroup initiated its Buy rating on June 17, 2025, with a $72 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when MOLINA ARTURO MD sold 2,712 shares for $84.77 per share. The transaction valued at 229,896 led to the insider holds 81,180 shares of the business.
Waddill William D. sold 12,000 shares of PTGX for $979,480 on Oct 10 ’25. The Director now owns 5,130 shares after completing the transaction at $81.62 per share. On Oct 10 ’25, another insider, WILLIAM WADDILL, who serves as the Director of the company, bought 12,000 shares for $67.04 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTGX now has a Market Capitalization of 5464494592 and an Enterprise Value of 4899126272. As of this moment, Protagonist’s Price-to-Earnings (P/E) ratio for their current fiscal year is 138.00, and their Forward P/E ratio for the next fiscal year is 102.42. For the stock, the TTM Price-to-Sale (P/S) ratio is 26.12 while its Price-to-Book (P/B) ratio in mrq is 8.46. Its current Enterprise Value per Revenue stands at 23.416 whereas that against EBITDA is 244.589.
Stock Price History:
The Beta on a monthly basis for PTGX is 2.26, which has changed by 1.1895673 over the last 52 weeks, in comparison to a change of 0.13153219 over the same period for the S&P500. Over the past 52 weeks, PTGX has reached a high of $96.54, while it has fallen to a 52-week low of $33.70. The 50-Day Moving Average of the stock is 4.89%, while the 200-Day Moving Average is calculated to be 43.61%.
Shares Statistics:
Over the past 3-months, PTGX traded about 1.19M shares per day on average, while over the past 10 days, PTGX traded about 1291840 shares per day. A total of 62.45M shares are outstanding, with a floating share count of 59.09M. Insiders hold about 5.47% of the company’s shares, while institutions hold 110.21% stake in the company. Shares short for PTGX as of 1764288000 were 5883017 with a Short Ratio of 4.93, compared to 1761868800 on 5465729. Therefore, it implies a Short% of Shares Outstanding of 5883017 and a Short% of Float of 11.270001.
Earnings Estimates
Protagonist Therapeutics Inc (PTGX) is presently subject to a detailed evaluation by 9.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.43, with high estimates of $0.06 and low estimates of -$0.75.
Analysts are recommending an EPS of between -$1.26 and -$2.33 for the fiscal current year, implying an average EPS of -$1.87. EPS for the following year is $1.06, with 9.0 analysts recommending between $5.04 and -$2.36.
Revenue Estimates
A total of 11 analysts have provided revenue estimates for PTGX’s current fiscal year. The highest revenue estimate was $258.9M, while the lowest revenue estimate was $38.58M, resulting in an average revenue estimate of $66.81M. In the same quarter a year ago, actual revenue was $434.43MBased on 10 analysts’ estimates, the company’s revenue will be $273.47M in the next fiscal year. The high estimate is $525M and the low estimate is $20M.
